# Audience Intelligence: Drug-price transparency for self-funded health plans

Benefits lead or CFO at a self-funded employer is the first audience because the report already names a repeated pain, reachable channels, and a validation test that can be run before software is complete.

## Segments
- **Benefits lead or CFO at a self-funded employer**: Self-funded employers pay pharmacy claims through PBM contracts whose spreads, rebates, and formulary steering they cannot see, routinely overpaying for drugs with cheaper therapeutic equivalents. Trigger: Employers have won headline lawsuits and congressional attention over PBM spread pricing and rebate opacity. Budget signal: Annual per-employee-per-year analytics fee, standard in benefits tooling.
- **Budget owner who feels the operational cost of the broken workflow.**: Well-funded benefits-analytics incumbents are racing into the same disclosure data. Trigger: AI-assisted product work and managed infrastructure reduce the first-version cost. Budget signal: $49-$499/month
- **Hands-on operator willing to pilot a narrow tool before a full rollout.**: PBM contract complexity means findings must survive pushback from sophisticated counterparties. Trigger: Annual per-employee-per-year analytics fee, standard in benefits tooling. Budget signal: $99-$1,000/year add-on
- **Benefits lead or CFO at a self-funded employer who still run the workflow in spreadsheets, generic docs, email, or chat threads.**: Self-funded employers pay pharmacy claims through PBM contracts whose spreads, rebates, and formulary steering they cannot see, routinely overpaying for drugs with cheaper therapeutic equivalents. Trigger: The wedge is specific enough to test without claiming the whole market. Budget signal: Custom

## Channels
- **Reddit / forums**: Look for complaints, workarounds, and repeated questions. First move: Post a problem teardown for Employer health benefits analytics and ask how people solve it today.
- **Launch communities**: Launch traction shows whether the promise is legible. First move: Ship a narrow demo and watch which promise gets clicks.
- **Review and alternative pages**: Pricing and alternatives expose buyer objections. First move: Write an alternatives page that owns one narrow use case.
- **Community pain posts**: Use communities and forums where Benefits lead or CFO at a self-funded employer already describe the painful workflow. First move: Problem teardown, interview ask, and short demo clip
- **Direct outreach**: Direct conversations are the fastest way to verify budget ownership and switching cost. First move: Concierge pilot offer with a manually prepared sample

## Intent Keywords
`drug workflow`, `price validation`, `drug ai`, `price automation`, `price-transparency`, `healthtech`, `Employer health benefits analytics`

## Messaging Angles
- Drug-price transparency for self-funded health plans should be tested as a narrow first-win workflow for one buyer: Benefits lead or CFO at a self-funded employer.
- Replace a narrow workflow that reaches value without configuration-heavy onboarding. with a focused first-win workflow.
- Promise proof around problem resonance: 5+ calls or 10+ detailed replies..
- De-risk adoption with concierge review or paid template.

## Objections
- Well-funded benefits-analytics incumbents are racing into the same disclosure data.
- PBM contract complexity means findings must survive pushback from sophisticated counterparties.
- Needs real buyer access, not only desk research.
- Needs proof of budget or repeated urgency.
- Needs a crisp wedge before broad product work starts.
- A broad AI assistant can flatten differentiation unless the wedge is painfully specific.